(NASDA SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

1 Day GPCR -1.32% DJIA -0.27% S&P Mid Cap 400 -0.28% Health Care/Life Sciences -0.79% ...

In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore Structure Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GPCR. Pfizer ends danuglipron development after liver safety issue ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. Analyst Price Forecast Suggests ...

1 Day GPCR 3.03% DJIA 0.78% S&P Mid Cap 400 1.06% Health Care/Life Sciences -1.25% ...